.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 9,044,485

« Back to Dashboard

Details for Patent: 9,044,485

Title:Ceftolozane antibiotic compositions
Abstract: This disclosure provides pharmaceutical compositions comprising ceftolozane, pharmaceutical compositions comprising ceftolozane and tazobactam, methods of preparing those compositions, and related methods and uses of these compositions.
Inventor(s): Terracciano; Joseph (Concord, MA), Damour; Nicole Miller (Belmont, MA), Lan; Yanmei (Acton, MA), Ly; Jonathan Cam (Arlington, MA), Zhou; Jianxun (Windham, NH)
Assignee: CALIXA THERAPEUTICS, INC. (Lexington, MA)
Filing Date:Apr 11, 2014
Application Number:14/251,372
Claims:1. An antibiotic pharmaceutical product comprising a compound of formula (I) ##STR00018## or a pharmaceutically acceptable salt thereof, stabilized with a non-reducing sugar in an amount effective to reduce the rate of degradation of the compound of formula (I), degradation product having the structure of formula (IV) ##STR00019## and the compound of formula (I) being stabilized by obtaining the compound of formula (I) in the antibiotic pharmaceutical composition by a process comprising the steps of: a. lyophilizing an aqueous solution comprising a stabilizing-effective amount of the non-reducing sugar as a ceftolozane stabilizing agent and the compound of formula (I) or a pharmaceutically acceptable salt thereof at a pH of about 5-7 to obtain a lyophilized stabilized composition; and b. combining the lyophilized stabilized composition of step (a) with a composition comprising a compound of formula (II) ##STR00020## or a pharmaceutically acceptable salt thereof, to obtain the antibiotic pharmaceutical product.

2. The antibiotic pharmaceutical product of claim 1, wherein the antibiotic pharmaceutical product is obtained by combining the compound of formula (II) with a compound of formula (I) lyophilized in the absence of a compound of formula (II).

3. The antibiotic pharmaceutical product of claim 1, comprising the compound of formula (II) or a pharmaceutically acceptable salt thereof in an amount providing a 2:1 weight ratio of the compound of formula (I) to the compound of formula (II) in the antibiotic pharmaceutical product.

4. An antibiotic pharmaceutical product comprising a compound of formula (I) ##STR00021## or a pharmaceutically acceptable salt thereof, a compound of formula (IV) ##STR00022## the compound of formula (I) being obtained by a process comprising the steps of: a. lyophilizing an aqueous solution comprising a stabilizing-effective amount of a non-reducing sugar to reduce the rate of degradation of the compound of formula (I), and the compound of formula (I) or a pharmaceutically acceptable salt thereof to obtain a lyophilized composition; and b. combining the lyophilized composition of step (a) with a composition comprising a compound of formula (II) ##STR00023## or a pharmaceutically acceptable salt thereof, to obtain the antibiotic pharmaceutical product.

5. The antibiotic pharmaceutical product of claim 4, wherein the aqueous solution comprising a compound of formula (I) is lyophilized in the absence of a compound of formula (II).

6. The antibiotic pharmaceutical product of claim 4, where the compound of formula (II) or a pharmaceutically acceptable salt thereof and the lyophilized stabilized composition are combined in an amount providing a 2:1 weight ratio of the compound of formula (I) to the compound of formula (II) in the antibiotic pharmaceutical product.

7. The antibiotic pharmaceutical product of claim 4, wherein the aqueous solution further comprises a ceftolozane stabilizing agent and an alkalizing agent in an amount effective to adjust the pH to about 5-7 prior to lyophilization.

8. The antibiotic pharmaceutical product of claim 4, wherein the lyophilized stabilized composition further comprises one or more compounds selected from the group consisting of a. a compound of formula (V) ##STR00024## b. compound of formula (VI) ##STR00025## and c. a compound of formula (VII) ##STR00026##

9. The antibiotic pharmaceutical product of claim 4, further characterized by one or more aspects selected from the group consisting of: a. a sodium salt of the compound of formula (II) is combined with the lyophilized stabilized compound of formula (I); b. the aqueous solution further comprises an alkalizing agent in an amount effective to adjust the pH to about 5-7 prior to lyophilization; ##STR00027## c. the lyophilized stabilized composition further comprises one or more compounds selected from the group consisting of i. a compound of formula (V) ##STR00028## ii. a compound of formula (VI) ##STR00029## and iii. a compound of formula (vii) ##STR00030##

10. An antibiotic pharmaceutical product comprising a compound of formula (I) ##STR00031## or a pharmaceutically acceptable salt thereof; a non-reducing sugar in an amount effective to reduce the rate of degradation of the compound of formula (I) in the antibiotic pharmaceutical product; a degradation product of the compound of formula (I) having the structure of formula (IV) ##STR00032## and a compound of formula (II), ##STR00033## or a pharmaceutically acceptable salt thereof.

11. The composition of claim 10, where the compound of formula (II) or a pharmaceutically acceptable salt thereof and the lyophilized stabilized composition are combined in an amount providing a 2:1 weight ratio of the compound of formula (I) to the compound of formula (II) in the antibiotic pharmaceutical product.

12. The composition of claim 10, wherein a sodium salt of the compound of formula (II) is combined with the lyophilized stabilized compound of formula (I).

13. The composition of claim 10, wherein the aqueous solution further comprises a ceftolozane stabilizing agent and an alkalizing agent in an amount effective to adjust the pH to about 5-7 prior to lyophilization.

14. An antibiotic pharmaceutical product comprising: a compound of formula (I) ##STR00034## or a pharmaceutically acceptable salt thereof, stabilized by a non-reducing sugar; and a compound of formula (II) ##STR00035## or a pharmaceutically acceptable salt thereof.

15. The antibiotic pharmaceutical product of claim 1, wherein the non-reducing sugar is selected from the group consisting of trehalose and sucrose.

16. The antibiotic pharmaceutical product of claim 1, wherein the aqueous solution comprises at least about 300 mg of the non-reducing sugar per 1 g of the compound of formula (I).

17. The antibiotic pharmaceutical product of claim 3, wherein the aqueous solution comprises at least about 300 mg of the non-reducing sugar per 1 g of the compound of formula (I).

18. The antibiotic pharmaceutical product of claim 17, wherein the non-reducing sugar is selected from the group consisting of trehalose and sucrose.

19. The antibiotic pharmaceutical product of claim 18, comprising 1,000 mg of the compound of formula (I) and 500 mg of the compound of formula (II) in a unit dosage form.

20. The antibiotic pharmaceutical product of claim 14, wherein the antibiotic pharmaceutical product is a reconstituted liquid for intravenous administration, comprising compound of formula (I) and the compound of formula (II).

21. The antibiotic pharmaceutical product of claim 1, wherein the antibiotic pharmaceutical product is obtained by a process further comprising the step of: c. reconstituting the lyophilized stabilized composition; wherein the reconstituted lyophilized stabilized composition from step (c) is combined with composition comprising the compound of formula (II) to obtain the reconstituted liquid for intravenous administration.

22. The antibiotic pharmaceutical product of claim 14, comprising a. a first container with the lyophilized stabilized composition comprising the compound of formula (I) or a pharmaceutically acceptable salt thereof, without the compound of formula (II); and b. a second container with the composition comprising the compound of formula (II) or a pharmaceutically acceptable salt thereof, without the compound of formula (I).

23. The antibiotic pharmaceutical product of claim 14, comprising a single container comprising the lyophilized stabilized composition comprising the compound of formula (I) or a pharmaceutically acceptable salt thereof and the composition comprising the compound of formula (II) or a pharmaceutically acceptable salt thereof.

24. The antibiotic pharmaceutical product of claim 23, wherein the product is a solid powder within the single container.

25. The antibiotic pharmaceutical product of claim 1, wherein the aqueous solution comprises an amount of the non-reducing sugar effective to reduce the amount of degradation of the compound of formula (I) in the lyophilized stabilized composition of step (a) at 60 degrees C. for 7 days.

26. The antibiotic pharmaceutical product of claim 1, wherein the aqueous solution comprises an amount of the non-reducing sugar effective to increase the purity of the compound of formula (I) in the antibiotic pharmaceutical product at 60 degrees C. for 7 days.

27. The antibiotic pharmaceutical product of claim 4, wherein the aqueous solution comprises an amount of the non-reducing sugar effective to increase the purity of the compound of formula (I) in the lyophilized stabilized composition of step (a) at 60 degrees C. for 7 days.

28. The antibiotic pharmaceutical product of claim 10, wherein the antibiotic pharmaceutical product comprises an amount of the non-reducing sugar effective to increase the purity of the compound of formula (I) in the lyophilized stabilized composition of step (a) at 60 degrees C. for 7 days.

29. The antibiotic pharmaceutical product of claim 14, wherein the antibiotic pharmaceutical product comprises an amount of the non-reducing sugar effective to increase the purity of the compound of formula (I) in the lyophilized stabilized composition of step (a) at 60 degrees C. for 7 days.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc